



## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/659,324	09/11/2003	Birger Sorensen	02833.4001LO	3291
5514 75	12/13/2005		EXAM	INER
	K CELLA HARPER &	STUCKER,	STUCKER, JEFFREY J	
* · · · · · · · · · · · · · · · · · · ·	30 ROCKEFELLER PLAZA NEW YORK, NY 10112			PAPER NUMBER
,			1648	

DATE MAILED: 12/13/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/659,324	SORENSEN, BIRGER				
Office Action Summary	Examiner	Art Unit				
	Jeffrey Stucker	1648				
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING C  - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period  - Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailine earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 136(a). In no event, however, may a reply be tim will apply and will expire SIX (6) MONTHS from e, cause the application to become ABANDONE	l. ely filed the mailing date of this communication. O (35 U.S.C. § 133).				
Status .						
1) Responsive to communication(s) filed on 7/27	Responsive to communication(s) filed on 7/21/05 & 10/19/05.					
<u> </u>	s action is non-final.					
3) Since this application is in condition for allowa	, <del></del>					
closed in accordance with the practice under	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4) ☐ Claim(s) <u>16-33,35,37-45,47 and 49-52</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) <u>16-33,35,37-45,47 and 49-52</u> are su	oject to restriction and/or election i	requirement.				
Application Papers						
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) acc	cepted or b) $\square$ objected to by the E	Examiner.				
Applicant may not request that any objection to the	drawing(s) be held in abeyance. See	37 CFR 1.85(a).				
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list	of the certified copies not receive	d.				
Attachment(s)						
1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)						
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	te				
<ul> <li>Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)</li> <li>Paper No(s)/Mail Date</li> </ul>	5)  Notice of Informal Page 6) Other:	atent Application (PTO-152)				

Application/Control Number: 10/659,324
Art Unit: 1648

Applicant's election with traverse of Group IV on 7/21/05 and the election of species with traverse of SEQ ID NO: 18 in the reply filed 10/19/05 are acknowledged. However, Applicant has amended the claims to include additional claims and group(s) prior the issuance of a First Action on the Merits. A Supplemental Restriction is therefore required. See below. Claims 16-33, 35, 37-45, 47, and 49-52 are pending.

Restriction to one of the following inventions is required under 35 U.S.C. § 121:

- I. Claims 16-33, 35, and 37-44, drawn to methods of stimulating the immune system, classified in Class 424, subclass 208.1.
- II. Claims 45, 47, and 49-52, drawn to peptides, classified in Class 530, subclass 350.

The inventions are distinct, each from the other because of the following reasons:

Inventions II and I are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP

§ 806.05(h)). In the instant case, the peptides can be used in immunoassays or affinity purification.

Page 3

If Applicant elects Group I, he is further required to elect one of:

SEQ ID NO: 1,

SEQ ID NO: 4,

SEQ ID NO: 9,

SEQ ID NO: 15,

The inventions are distinct, each from the other because of the following reasons:

Each of the different sequences are independent and distinct inventions because the claimed compounds do not share a common utility nor share a substantial structural feature disclosed as being essential to that utility. Accordingly, these sequences are each subject to restriction under 35 U.S.C. § 121. Applicant is required to elect a single sequence, which if determined to be patentable, would also be patentably distinct from other sequences.

If Applicant elects Group II, he is further required to elect one of:

SEQ ID NO: 1,

Application/Control Number: 10/659,324
Art Unit: 1648

SEQ ID NO: 4, SEQ ID NO: 9,

SEQ ID NO: 15,

The inventions are distinct, each from the other because of the following reasons:

Each of the different sequences are independent and distinct inventions because the claimed compounds do not share a common utility nor share a substantial structural feature disclosed as being essential to that utility. Accordingly, these sequences are each subject to restriction under 35 U.S.C. § 121. Applicant is required to elect a single sequence, which if determined to be patentable, would also be patentably distinct from other sequences.

Because these inventions are distinct for the reasons given above and have acquired separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

This application contains claims directed to the following patentably distinct species of the claimed invention: each of the variants of the sequences set forth in the claims is considered to be a species of the specific, recited, SEQ ID NO.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

Page 5

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Art Unit: 1648

Papers related this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG (November 15, 1989).

The Group 1600 Official Fax number is: (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Tech Center representative whose telephone number is (571)-272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey Stucker whose telephone number is (571)-272-0911. The examiner can normally be reached Monday to Thursday from 7:00am-3:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel, can be reached on (571)-272-0902.

JEFFREY STUCKER PRIMARY EXAMINER